Literature DB >> 17869148

Mechanism of decongestant activity of alpha 2-adrenoceptor agonists.

M R Corboz1, M A Rivelli, G G Mingo, R L McLeod, L Varty, Y Jia, J A Hey.   

Abstract

The vascular bed in nasal mucosa of different species, including human, is highly vascularized and an extensive sinusoidal network of large capacitance vessels is present deep within the submucosa. When this network of venous sinusoids is engorged with blood, the swollen mucosa reduces the size of the airway lumen and congestion ensues. Nasal vasculature tone is strongly influenced by the sympathetic nervous system and the only drugs approved specifically to relieve vascular nasal obstruction are alpha-adrenoceptor sympathomimetic agents. Due to their vasoconstrictor action, the sympathomimetic decongestants oppose vasodilation, reducing nasal airway resistance and thus facilitating nose breathing. However, standard decongestants that are non-selective alpha-adrenoceptor agonists are associated with the potential for side-effect liabilities including hypertension, stroke, insomnia and nervousness. We propose than a selective alpha 2-adrenoceptor agonist, by acting preferentially on nasal venous capacitance vessels, will elicit decongestion with a reduced side-effect liability. In the present study, we evaluated the effects of the selective alpha 2-adrenoceptor agonist BHT-920 in a real-time tissue contractility assay using isolated pig nasal explants and in an in vivo cat model of congestion. The vasoconstrictor and decongestant effects of BHT-920 were compared to the non-selective alpha-adrenoceptor agonist epinephrine and the standard decongestant oxymetazoline. Our results showed that the alpha 2-adrenoceptor agonist BHT-920 preferentially contracts venous sinusoids confirming previous observations [Corboz MR, Varty LM, Rivelli MA, Mutter JC, Mingo G, McLeod R, et al. Effects of an alpha 2-adrenoceptor agonist in nasal mucosa. Arch Physiol Biochem 2003;11: 335-6, Corboz MR, Rivelli MA, Varty LM, Mutter J, Cartwright M, Rizzo CA, et al. Pharmacological characterization of postjunctional alpha-adrenoceptor in human nasal mucosa. Am J Rhinol 2005;19: 495-502] and displays decongestion without affecting blood pressure. Therefore, an alpha 2-adrenoceptor agonist, by causing constriction in the capacitance vessels of nasal mucosa, can produce nasal decongestion without the effects on blood pressure observed with the standard selective alpha 1-adrenoceptor and non-selective alpha-adrenoceptor sympathomimetic decongestants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869148     DOI: 10.1016/j.pupt.2007.06.007

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  9 in total

Review 1.  Rhinitis medicamentosa: what an otolaryngologist needs to know.

Authors:  Jayesh Doshi
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-19       Impact factor: 2.503

2.  Endothelin-1 and its receptors on haemorrhoidal tissue: a potential site for therapeutic intervention.

Authors:  Varut Lohsiriwat; John H Scholefield; Vincent G Wilson; Michael R Dashwood
Journal:  Br J Pharmacol       Date:  2017-02-16       Impact factor: 8.739

3.  Scientific rationale for the use of alpha-adrenergic agonists and glucocorticoids in the therapy of pediatric stridor.

Authors:  Gustavo Nino; Orkun Baloglu; Maria J Gutierrez; Michael Schwartz
Journal:  Int J Otolaryngol       Date:  2011-12-19

4.  Safety and efficacy of phenylephrine nasal drops in bronchiolitis.

Authors:  Gholamreza Soleimani; Marzieh Akbarpour; Mehdi Mohammadi
Journal:  Iran J Pediatr       Date:  2014-10-05       Impact factor: 0.364

5.  Impact of self-reported symptoms of allergic rhinitis and asthma on sleep disordered breathing and sleep disturbances in the elderly with polysomnography study.

Authors:  Sae-Hoon Kim; Ha-Kyeong Won; Sung-Do Moon; Byung-Keun Kim; Yoon-Seok Chang; Ki-Woong Kim; In-Young Yoon
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

6.  Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.

Authors:  Eugene McLaurin; Megan E Cavet; Paul J Gomes; Joseph B Ciolino
Journal:  Optom Vis Sci       Date:  2018-03       Impact factor: 1.973

7.  Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.

Authors:  Stacey L Ackerman; Gail L Torkildsen; Eugene McLaurin; Jason L Vittitow
Journal:  Clin Exp Optom       Date:  2018-12-07       Impact factor: 2.742

8.  Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Authors:  Mustafa Cenk Ecevit; Müge Özcan; İlknur Haberal Can; Emel Çadallı Tatar; Serdar Özer; Erkan Esen; Doğan Atan; Sercan Göde; Çağdaş Elsürer; Aylin Eryılmaz; Berna Uslu Coşkun; Zahide Mine Yazıcı; Mehmet Emre Dinç; Fatih Özdoğan; Kıvanç Günhan; Nagihan Bilal; Arzu Yasemin Korkut; Fikret Kasapoğlu; Bilge Türk; Ela Araz Server; Özlem Önerci Çelebi; Tuğçe Şimşek; Rauf Oğuzhan Kum; Mustafa Kemal Adalı; Erdem Eren; Nesibe Gül Yüksel Aslıer; Tuba Bayındır; Aslı Çakır Çetin; Ayşe Enise Göker; Işıl Adadan Güvenç; Sabri Köseoğlu; Gül Soylu Özler; Ethem Şahin; Aslı Şahin Yılmaz; Ceren Güne; Gökçe Aksoy Yıldırım; Bülent Öca; Mehmet Durmuşoğlu; Yunus Kantekin; Süay Özmen; Gözde Orhan Kubat; Serap Köybaşı Şanal; Emine Elif Altuntaş; Adin Selçuk; Haşmet Yazıcı; Deniz Baklacı; Atılay Yaylacı; Deniz Hancı; Sedat Doğan; Vural Fidan; Kemal Uygur; Nesil Keleş; Cemal Cingi; Bülent Topuz; Salih Çanakçıoğlu; Metin Önerci
Journal:  Turk Arch Otorhinolaryngol       Date:  2021-05

9.  Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model.

Authors:  Richard Tuttle; Luca Popescu; Scott Hill; Amber Slanczka; Jeffrey Jankowski; Katherine Barre; Erika Krueger; Desmond Slade; Claire Croutch; Matthew Robben; Zack Mesa; Michael Mesa; Kenneth L Dretchen
Journal:  Respir Res       Date:  2020-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.